Altheus Therapeutics, Inc. is developing Zoenasa® Oral Tablets and Rectal Gel formulations as novel front-line therapies for the treatment of ulcerative colitis and other inflammatory bowel diseases (IBD). Current front-line therapy for ulcerative colitis is the anti-inflammatory mesalamine (5-aminosalicylic acid; 5-ASA). Zoenasa is a fixed-dose combination of mesalamine plus the powerful antioxidant and anti-inflammatory agent N-acetylcysteine to reduce mucosal injury associated with inflammatory bowel disease.

Zoenasa will be available as Oral Tablets with an extended- and delayed-release profile for long term therapy in patients with proximal or extensive colitis; as a Rectal Gel for short term therapy in patients suffering from left-sided (distal) ulcerative colitis; and in other specialized formulations. In both animal and human research studies, the Zoenasa combination has demonstrated dramatic efficiacy benefits over mesalamine monotherapy. Altheus believes that Zoenasa will open an important new category in ulcerative colitis, mesalamine combination therapy.

SEC Filings show all

D6

Overview

Total FundingEmployeesLast Funding DateStatus
$10,055,9481-102013-01-04Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2011-12-08$1,970,243Debt_financing
2013-01-04$8,085,705Private_equity

Key Executives

  • Richard F Harty, MD
    Executive Officer, Promoter
  • Brian L Clevinger
    Executive Officer, Director
  • Douglas A Branch
    Executive Officer
  • William Paiva
    Director
  • Alpha BioPartners, Inc.
    Promoter
  • Thomas L Shoaf
    Director
  • James Schoeneck
    Director
  • Dennis Schafer
    Executive Officer, Director
  • Richard F. Harty, MD
    Executive Officer, Promoter
  • Brian L. Clevinger
    Executive Officer, Director
  • Thomas L. Shoaf
    Director
  • Douglas A. Branch
    Director